Regenxbio Target Price

See Regenxbio's analyst price targets ($22) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$8.94

Average Target Price

$21.67

142.4% upside

9 analysts in the last 4 months

High: $32 | Low: $12

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-25	H.C. WainwrightYi Chen	$21	134.9% upside
2026-08-25	Robert W. BairdBrian Skorney	$29	224.4% upside
2026-08-10	H.C. Wainwright	$23	157.3% upside
2026-08-07	Morgan StanleyJudah Frommer	$18	101.3% upside
2026-07-01	H.C. WainwrightYi Chen	$26	190.8% upside
2026-06-22	Leerink PartnersMani Foroohar	$18	101.3% upside
2026-06-22	Robert W. BairdBrian Skorney	$32	257.9% upside
2026-05-15	Morgan Stanley	$16	79% upside
2026-05-15	BarclaysEliana Merle	$12	34.2% upside
2026-03-09	H.C. Wainwright	$30	235.6% upside
2026-03-05	Morgan StanleyJudah Frommer	$17	90.2% upside
2026-02-10	H.C. Wainwright	$32	257.9% upside
2026-02-10	Robert W. BairdBrian Skorney	$27	202% upside
2026-02-10	UBS	$18	101.3% upside
2026-02-10	Goldman Sachs	$12	34.2% upside
2026-01-29	H.C. WainwrightYi Chen	$34	280.3% upside
2026-01-27	Barclays	$37	313.9% upside
2025-12-19	Stifel Nicolaus	$45	403.4% upside
2025-12-15	Leerink PartnersMani Foroohar	$20	123.7% upside
2025-03-18	Leerink Partners	$24	168.5% upside
2025-01-07	RBC CapitalLuca Issi	$30	235.6% upside
2024-11-15	Morgan StanleyJudah Frommer	$22	146.1% upside
2024-10-10	Raymond JamesDanielle Brill	$18	101.3% upside
2024-09-05	H.C. WainwrightYi Chen	$39	336.2% upside
2024-06-24	Stifel NicolausAnnabel Samimy	$40	347.4% upside
2024-06-07	Goldman SachsPaul Choi	$38	325.1% upside
2024-05-15	H.C. WainwrightYi Chen	$38	325.1% upside
2024-03-11	H.C. WainwrightYi Chen	$36	302.7% upside
2024-03-08	RBC CapitalLuca Issi	$35	291.5% upside

Regenxbio (RGNX) FAQ

As of the most recent data, RGNX shows a target price of $22. Scroll down for historical charts and peer comparison views.

If Regenxbio moved to the average analyst target of $22, shares would be roughly 142.4% higher than $8.94. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Regenxbio's earnings trajectory.

Besides this target price page, Stockcircle has Regenxbio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $22) with ownership activity and broader fundamentals.

Regenxbio's target price is $22; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.